²Î¿¼ÎÄÏ×/References:
[1] JEE Y. WHO International Health Regulations Emergency Committee for the COVID-19 outbreak[J]. Epidemiol health,2020,42:e2020013.
[2]HSIEH C C,LIN C H,WANG W Y C,et al. The outcome and implications of public precautionary measures in taiwan-declining respiratory disease cases in the COVID-19 pandemic[J]. International journal of environmental research and public health,2020,17(13):4877.
[3]LU R,ZHAO X,LI J,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
[4]DAI Y,CHEN S R,CHAI L,et al. Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide[J]. Critical revriews in food science and nutrition,2019,59(sup1):S17-S29.
[5]ZHOU P,YANG X L,WANG X G,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.
[6]WU C,LIU Y,YANG Y,et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods[J]. Acta pharmaceutica sinica B,2020,10(5):766-788.
[7]LI W,XU C,HAO C,et al. Inhibition of herpes simplex virus by myricetin through targeting viral gD protein and cellular EGFR/PI3K/Akt pathway[J]. Antiviral research,2020,177:104714.
[8]ANAND K,PALM G J,MESTERS J R,et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain[J]. The embo journal,2002,21(13):3213-3224.
[9]ZHOU J,FANG L,YANG Z,et al. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach[J]. The faseb journal,2019,33(12):14575-14587.
[10]ANAND K,ZIEBUHR J,WADHWANI P,et al. Coronavirus main proteinase(3CLpro)structure:basis for design of anti-SARS drugs[J]. Science,2003,300(5626):1763-1767.
[11]PILLAIYAR T,MANICKAM M,NAMASIVAYAM V,et al. An overview of severe acute respiratory syndrome-coronavirus(SARS-CoV)3CL protease inhibitors:peptidomimetics and small molecule chemotherapy[J]. Journal of medicinal chemistry,2016,59(14):6595-6628.
[12]DONG L,HU S,GAO J. Discovering drugs to treat coronavirus disease 2019(COVID-19)[J]. Drug discoveries & therapeutics,2020,14(1):58-60.
[13]CAO B,WANG Y,WEN D,et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19[J]. New England journal of medicine,2020,382(19):1787-1799.
[14]³Â¾ü,ÁèÔÆ,ϯÐãºì. ÂåÆ¥ÄÇΤÀûÍÐÄÇΤºÍ°¢±È¶à¶ûÓÃÓÚÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ×µÄÓÐЧÐÔÑо¿[J]. Öлª´«È¾²¡ÔÓÖ¾,2020(2):86-89.
[15]VINCENT M J,BERGERON E,BENJANNET S,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virology journal,2005,2:69.
[16]ÓÚÃ÷À¤,²ñÙ»ÔÆ,Áº²ýê»,µÈ. ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÖÐÒ½Ô¤·À¼°ÕïÁÆ·½°¸»ã×Ü·ÖÎö[J]. ÖÐÒ½ÔÓÖ¾,2020,61(5):383-387.
[17]½ªð©,ÕÔÊ¿²©,ÕÅÒÕÜ°,µÈ. йڷÎÑ×ÖÐÒ½Ò©ÕïÖÎÔ¤·À¼°µØÇøÖÎÁÆÌØÉ«Ñо¿½øÕ¹[J]. ÖйúҽԺҩѧÔÓÖ¾,2020,40(17):1896-1901.
[18]ELMEZAYEN A D,AL-OBAIDI A, ÿðþ ‰C AHIN A T,et al. Drug repurposing for coronavirus(COVID-19):in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes[J]. Journal of biomolecular structure and dynamics,2021,29(8):2980-2992.
[19]JIN Z,DU X,XU Y,et al. Structure of M(pro)from SARS-CoV-2 and discovery of its inhibitors[J]. Nature,2020,582(7811):289-293.
[20]LIPINSKI C A. Chris Lipinski discusses life and chemistry after the Rule of Five[J]. Drug discovery today,2003,8(1):12-16.
[21]ÁÖÖ¾±ò,ÂÞ¿¡. ÁéÖ¥ÈýÝÆÀ໯ºÏÎïÒ©Àí×÷ÓÃÑо¿½øÕ¹[J]. ҩѧѧ±¨,2002,34(7):574-578.
[22]TSAO R,ATTYGALLE A B,SCHROEDER F C,et al. Isobutylamides of unsaturated fatty acids from Chrysanthemum morifolium associated with host-plant resistance against the western flower thrips[J]. Journal of natural products,2003,66(9):1229-1231.
[23]YUAN H,JIANG S,LIU Y,et al. The flower head of Chrysanthemum morifolium Ramat.(Juhua):A paradigm of flowers serving as Chinese dietary herbal medicine[J]. Journal of ethnopharmacology,2020,261:113043.
ÏàËÆÎÄÏ×/References:
[1]³£ÃÀ¼Ñ,ÂÞÊ¢,ÑîÐñÊï,µÈ.2£¬4-àçßòÍé¶þͪÀàÈ©ÌÇ»¹ÔøÒÖÖƼÁµÄÈýά¶¨Á¿½á¹¹-»îÐÔ¹Øϵ¼°·Ö×Ó¶Ô½ÓÑо¿[J].ÄϾ©Ê¦´óѧ±¨(×ÔÈ»¿Æѧ°æ),2015,38(03):31.
¡¡ChangMeijia,LuoSheng,YangXushu,et al.3D-QSARStudiesof2£¬4-ThiazolidinedionesasAldoseReductaseInhibitorsUsingCoMFA£¬CoMSIAandMolecularDocking[J].Journal of Nanjing Normal University(Natural Science Edition),2015,38(02):31.
[2]ÀèÓñ÷,ËÎ êÅ,μÎͯ,µÈ.±½±ûËáÀàeEF2KÒÖÖƼÁµÄÈýά¶¨Á¿¹¹Ð§¹Øϵ[J].ÄϾ©Ê¦´óѧ±¨(×ÔÈ»¿Æѧ°æ),2020,43(04):135.[doi:10.3969/j.issn.1001-4616.2020.04.019]
¡¡Li Yumei,Song Yu,Wen Jiatong,et al.Three-Dimensional Quantitative Structure-Activity Relationship ofPhenylpropionic Acid eEF2K Inhibitors[J].Journal of Nanjing Normal University(Natural Science Edition),2020,43(02):135.[doi:10.3969/j.issn.1001-4616.2020.04.019]